This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           January 28, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Veliparib trial fails to improve outcomes in ovarian cancer
Cancer Network
Use of the PARP inhibitor veliparib in combination with oral cyclophosphamide did not result in an improvement in response rate or median progression-free survival compared with treatment with cyclophosphamide alone, according to a phase II study evaluating patients with high-grade serous ovarian cancer, peritoneal, fallopian tube, and BRCA-mutant ovarian cancers. However, the study published in Clinical Cancer Research did demonstrate that oral cyclophosphamide was well-tolerated among this patient population and was associated with responses and prolonged disease stabilization.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


SGO Board of Directors and Foundation Council open election
The 2015 SGO Board of Directors and Foundation Council open election is now under way. All SGO members who are eligible to vote should have received an email from noreply@directvote.net on Monday, Jan. 12. The list of candidates for each position, including biographical information, personal statements and photos, is available for your consideration. Please take some time to review the candidates’ statements prior to casting your vote. Candidate information is also available on the ballot. Voting ends at 11:59 p.m. CST on Friday, Feb. 13.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


OVARIAN CANCER


Researchers pinpoint two genes that trigger severest form of ovarian cancer
Medical Xpress
In the battle against ovarian cancer, UNC School of Medicine researchers have created the first mouse model of the worst form of the disease and found a potential route to better treatments and much-needed diagnostic screens. "It's an extremely aggressive model of the disease, which is how this form of ovarian cancer presents in women," said Terry Magnuson, PhD, who is also a member of the UNC Lineberger Comprehensive Cancer Center. Not all mouse models of human diseases provide accurate depictions of the human condition. Magnuson's mouse model, though, is based on genetic mutations found in human cancer samples. The study was published recently in Nature Communications.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


CERVICAL CANCER


RNA test for HPV helps stratify cervical cancer risk
Cancer Network
A test for several dangerous strains of high-risk human papillomavirus (HPV) using messenger RNA was shown to be reliable and effective for cervical cancer risk stratification among women with atypical results of a Papanicolaou (Pap) test, according to the results of a new study. Results from the CLEAR study previously led to U.S. Food and Drug Administration of approval of genotype assay in October 2012. This new analysis reflex tested women with a positive test using a specific HPV 16 18/45 genotype assay (AHPV-GT) for further stratification.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HPV


HPV vaccine often not received at recommended age
HealthDay News via MPR
Only about half of American girls begin receiving the human papillomavirus (HPV) vaccine at the recommended age, according to a study to be published in the Jan. 29 issue of Vaccine. Girls should begin getting the three-dose HPV vaccine when they are 11 or 12. The vaccine is most effective before girls become sexually active, according to the U.S. Centers for Disease Control and Prevention. The CDC also recommends the vaccine for boys beginning at ages 11 or 12. However, the current study only looked at girls.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




ENDOMETRIAL CANCER


Oestrogen receptor ligands show promise for treating endometriosis
The Pharmaceutical Journal
Researchers studying endometriosis have discovered a potential way to treat the disease that avoids many of the side effects seen with existing therapies. Two compounds, chloroindazole (CLI) and oxabicycloheptene sulfonate (OBHS), which both bind to oestrogen receptors, were shown to control inflammation and reduce lesions in mice models without affecting fertility. The researchers, led by a team at the University of Illinois at Urbana-Champaign in the United States, say their work, published in Science Translational Medicine, has also provided greater insight into the causes and progression of the disease.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE


TREATMENT


Portable cervical cancer treatment may help women in remote areas receive care they need
Medical Daily
At one point cervical cancer was the most common cause of death for women in America under the age of 30. Today, thanks to increased use of the Pap smear test, the death rate from this form of cancer has gone down by 50 percent, The American Cancer Society reports. Unfortunately, this is not the case in many remote villages in developing countries. Here many women still do not get life-saving screenings for the cancer due to shame or simply not understanding the importance. A team of Peruvian doctors are working to change that. They hope to revamp an old dermatological device into a portable cervical cancer treatment which will be able to get the necessary help to the women who need it, no matter where they live.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MISS AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


BREAST CANCER


Breast cancer patients lack knowledge of their tumors
Reuters
Women with breast cancer often don’t know what kind of tumors they have, a new study published in Cancer found. Not knowing one’s tumor features isn’t necessarily tied to worse outcomes, but better knowledge might help women understand treatment decisions and take medications as directed, said Dr. Rachel Freedman, the study’s lead author from the Dana-Farber Cancer Institute in Boston. Also, she said, cancer patients who understand the basis for their treatment are generally more satisfied with that treatment.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HEALTH POLICY


'Historic' timeline set for basing Medicare pay on 'value'
Medscape (Free login required)
The Obama administration wants half of all Medicare payments to physicians and hospitals in 2018 to be made through alternative payment models such as medical homes and accountable care organizations (ACOs) as part of a "historic" timetable for basing reimbursement on value, not volume, the government announced today. In addition, the Department of Health and Human Services (HHS) has set a goal of tying 85 percent of all fee-for-service (FFS) payments to quality and cost measures by 2016, and 90 percent by 2018.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Jan. 21, 2015
Jan. 14, 2015
Jan. 7, 2015
Dec. 29, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063